Cardiac cachexia: Is it time to legalise anabolic agents?

Hellenic Journal of Cardiology

Volumn 45, Issue 5, 2004, Pages 282-287

  Filippatos, Gerasimos S ^a,b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Cardiac cachexia; Cytokines; Treatment

Indexed keywords

CYTOKINE;

ANOREXIA; CARDIAC CACHEXIA; DISEASE COURSE; HEART DISEASE; HEART FAILURE; MALNUTRITION; PATHOGENESIS; REVIEW;

EID: 5444246170     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Tisdale MJ: Cachexia in cancer patients. Nature reviews 2002; 2: 4-8
2. Filippatos G, Anker SD, Kardaras F: B-type natriuretic peptide serum levels in acute heart failure. Eur Heart J 2004; 25: 1085-1086
3. Mulligan K, Schambelan M: Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting Int J Cardiol 2002; 85: 151-159.
4. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241
5. Otaki M: Surgical treatment of patients with cardiac cachexia: an analysis of factors affecting operative mortality. Chest 1994; 105: 1347-1351
6. Freeman LM, Roubenhoff R: The nutrition implications of cardiac cachexia. Nutr Rev 1994; 52: 340-347.
7. Anker SD, Coats AJS: Cardiac cachexia. A syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999; 115: 836-847.
8. Anker SD, Ponikowski P, Varney S, et al: Wasting as independent risk factor of survival in chronic heart failure Lancet 1997; 349: 1050-1053.
9. Filippatos GS, Tsilias K, Venetsanou K, et al: Leptin serum levels in cachectic heart failure patients' relationship with tumor necrosis factor-a system Int J Cardiol 2000; 76: 117-122
10. Rosenberg IH: Sarcopenia: origins and clinical relevance J Nutr 1997; 127: 990S-991S.
11. Kotler D: Cachexia Ann Intern Med 2000; 133: 622-634.
12. Kotler DP, Thea DM, Heo M, et al: Relative influences of sex, race, environment and HIV infection upon body composition in adults Am J Clin Nutr 1999; 69: 432-439.
13. Forbes GB: Lean body mass-body fat interrelationships in humans. Nutr Rev 1987; 45: 225-231.
14. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ: Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999; 83: 612-615.
15. Toth MJ, Gottlieb SS, Goran MI, Fisher ML, Poehlman ET: Daily energy expenditure in free living heart failure patients. Am J Physiol 1997; 272: E469-475.
16. Thomas RD, Silverton NP, Burkinshaw L, Morgan DB: Potassium depletion and tissue loss in chronic heart failure. Lancet 1979; 310: 9-11.
17. Janssen JA, van der Lely AJ, Lamberts SW: Is there a role of ghrelin in preventing catabolism? J Endocrinol Invest 2004; 27: 400-403
18. Anker SD, Chua TP, Ponikowski P, et al: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534.
19. Anker SD, Ponikowski PP, Clark AL, et al: Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20: 683-693
20. Filippatos GS, Kanatselos C, Manolatos DD, et al: Studies on apoptosis and fibrosis in skeletal musculature a comparison of heart failure patients with and without cardiac cachexia. Int J Cardiol 2003; 90: 107-113.
21. Ajayi AA, Adigun AQ, Ojofeitimi EO, Yusuph H, Ajayi OE: Anthropometric evaluation of cachexia in chronic congestive heart failure, the role of tricuspid regurgitation. Int J Cardiol 1999; 71: 79-84.
22. Anker SD, Sharma R: The syndrome of cardiac cachexia. Int J Cardiol 2002; 85: 51-66
23. Obisesan TO, Toth MJ, Donaldson K, et al: Energy expenditure and symptom severity in men with heart failure. Am J Cardiol 1996, 77: 1250-1252.
24. Torre-Amione G, Kapadia S, Lee J, et al: Tumor necrosis factor alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711
25. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJS: Elevated soluble CD14 receptors and altered cytokines in chronic heart failure Am J Cardiol 1997; 79: 1426-1430.
26. Niebauer J, Volk HD, Kemp M, et al: Endotoxin and immune activation in chronic heart failure, a prospective cohort study Lancet 1999; 353: 1838-1842.
27. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD: Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19: 761-765.
28. Tsujinaka T, Fujita J, Ebisui C, et al: Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97: 244-249
29. Filippatos G, Leche C, Sunga R, et al: Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis. Am J Physiol. 1999; 277: H445-451.
30. Anker SD, Rauchhaus M: Heart failure as a metabolic problem. Eur J Heart Fail 1999; 1: 127-131
31. Sharma R, Anker SD Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002; 85: 161-171.
32. Schulze PC, Kratzsch J, Linke A, et al: Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure Eur J Heart Fail. 2003; 5: 33-40.
33. Filippatos G, Tsilias K, Baltopoulos G, Anthopoulos L: Serum leptin concentration in heart failure patients: does the literature reflect reality? Eur Heart J 2000; 21: 334-335.
34. Nagaya N, Kangawa K: Ghrelin improves left ventricular dysfunction, cardiac cachexia in heart failure: Curr Opin Pharmacol 2003; 3: 146-151.
35. Anker SD, Negassa A, Coats A, Poole-Wilson P, Yusuf S: Weight loss in chronic heart failure and the impact of treatment with ACE inhibitors - Results from the SOLVD treatment trial. Circulation 1999; 100: 1-781.
36. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN Jr. Effect of home total parenteral nutrition upon body composition in patients with acquired immunodeficiency syndrome J Parenter Enteral Nutr 1990; 14: 454-458.
37. Popp MB, Fisher RJ, Wesley R, Aamodt R, Brennan MF: A prospective randomised study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival. Surgery 1981; 90: 195-203.
38. Mustafa I, Leverve X. Metabolic and nutritional disorders in cardiac cachexia Nutrition 2001; 17: 756-760.
39. Piepoli MF, Davos C, Francis DP, Coats AJ: ExTraMATCH Collaborative Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004; 328: 189-193.
40. Coats AJS, Adamopoulos S, Radaelli A, et al: Controlled trial of physical training in chronic heart failure. Circulation 1992; 85: 2119-2131.
41. Schulze PC, Gielen S, Schuler G, Hambrecht R: Chronic heart failure and skeletal muscle catabolism: effects of exercise training. Int J Cardiol 2002; 85: 141-149.
42. Freeman L, Rush J, Kehayias J, et al: Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998; 12: 440-448.
43. Bozkurt B, Torre-Amione G, Warren MS, et al: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-1047.
44. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P: Randomised investigation of effects of pentoxyfilline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351: 1091-1093.
45. Skudicky D, Bergmann A, Sliwa K, Candy G, Sareli P: Beneficial effects of pentoxyfilline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation 2001; 103: 1083-1088.
46. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation J Exp Med 1993; 177: 1675-1680.
47. Davey PP, Ashrafian H: New therapies for heart failure: is thalidomide the answer? Q J Med 2000; 93: 305-311
48. Osterziel KJ, Strohm O, Schuler J, et al: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-1237.
49. Hryniewicz K, Androne AS, Hudaihed A, Katz SD: Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure J Card Fail 2003; 9: 464-468